The FDA approved daratumumab plus hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech) in combination with carfilzomib (Kyprolis, Amgen) and dexamethasone (Kd) for adults with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.
“Data from the PLEIADES trial continue to support additional treatment combinations that can influence the course of this disease as early as after the first relapse by providing durable responses that may help to delay